4/1
05:00 pm
vor
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
3/31
10:43 am
vor
Vor Biopharma (VOR) had its price target raised by Wedbush from $9.00 to $15.00. They now have a "neutral" rating on the stock.
Medium
Report
Vor Biopharma (VOR) had its price target raised by Wedbush from $9.00 to $15.00. They now have a "neutral" rating on the stock.
3/31
06:24 am
vor
Vor Biopharma (VOR) was upgraded by Jefferies Financial Group Inc. to "strong-buy".
High
Report
Vor Biopharma (VOR) was upgraded by Jefferies Financial Group Inc. to "strong-buy".
3/30
08:43 am
vor
Vor Biopharma (VOR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $50.00 price target on the stock.
Low
Report
Vor Biopharma (VOR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $50.00 price target on the stock.
3/30
08:01 am
vor
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Low
Report
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
3/30
08:00 am
vor
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
Low
Report
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
3/27
08:00 am
vor
Vor Bio Announces $75 Million Private Placement with TCGX
Medium
Report
Vor Bio Announces $75 Million Private Placement with TCGX
3/23
04:30 pm
vor
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/19
09:00 am
vor
Vor Biopharma (VOR) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $30.00 price target on the stock.
Low
Report
Vor Biopharma (VOR) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $30.00 price target on the stock.
2/23
08:00 am
vor
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
High
Report
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
1/23
05:09 am
vor
Vor Biopharma (NASDAQ:VOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Vor Biopharma (NASDAQ:VOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/9
08:02 am
vor
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $50.00 price target on the stock.
Low
Report
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $50.00 price target on the stock.
1/6
08:00 am
vor
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference